Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs

Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber A, Haschka J, Manger B, Kleyer A, Reiser M, Finzel S, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Rech J, Schett G (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 76

Pages Range: 399-407

Journal Issue: 2

DOI: 10.1136/annrheumdis-2016-209297

Abstract

To perform a detailed analysis of the autoantibody response against post-translationally modified proteins in patients with rheumatoid arthritis (RA) in sustained remission and to explore whether its composition influences the risk for disease relapse when tapering disease modifying antirheumatic drug (DMARD) therapy.Immune responses against 10 citrullinated, homocitrullinated/carbamylated and acetylated peptides, as well as unmodified vimentin (control) and cyclic citrullinated peptide 2 (CCP2) were tested in baseline serum samples from 94 patients of the RETRO study. Patients were classified according to the number of autoantibody reactivities (0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination, carbamylation and acetylation; 0-3) and tested for their risk to develop relapses after DMARD tapering. Demographic and disease-specific parameters were included in multivariate logistic regression analysis for defining the role of autoantibodies in predicting relapse.Patients varied in their antimodified protein antibody response with the extremes from recognition of no (0/10) to all antigens (10/10). Antibodies against citrullinated vimentin (51%), acetylated ornithine (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011) increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity) to 28%, 36% and finally to 52% with one, two or three antibody specificity groups, respectively.The data suggest that the pattern of antimodified protein antibody response determines the risk of disease relapse in patients with RA tapering DMARD therapy.2009-015740-42; Results.

Authors with CRIS profile

Involved external institutions

ORGENTEC Diagnostika GmbH Germany (DE) Eberhard Karls Universität Tübingen Germany (DE) Schlosspark-Klinik Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE) Asklepios Kliniken Germany (DE) Medias Klinikum Germany (DE) St. Vincentius-Kliniken / ViDia Kliniken Germany (DE)

How to cite

APA:

Figueiredo, C.P., Bang, H., Cobra, J.F., Englbrecht, M., Hueber, A., Haschka, J.,... Schett, G. (2017). Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 76(2), 399-407. https://doi.org/10.1136/annrheumdis-2016-209297

MLA:

Figueiredo, Camille P., et al. "Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs." Annals of the Rheumatic Diseases 76.2 (2017): 399-407.

BibTeX: Download